Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
StoneX Group Inc. - Common Stock
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Genprex, Inc. - Common Stock
(NQ:
GNPX
)
1.450
-0.220 (-13.17%)
Delayed Quote
Updated: 4:00 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Genprex, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Highly Promising Data Identifying TROP2 as Potential Predictive Biomarker for Reqorsa® Gene Therapy in Lung Cancer: Genprex, Inc. (Nasdaq: GNPX)
November 19, 2026
Via
Get News
Promising Gene Therapy Supporting Applications Beyond Oncology; Key Presentation at Upcoming Gerontological Society of America Meeting: Genprex, Inc. (Nasdaq: GNPX)
October 29, 2026
Via
Get News
TOMI Environmental (NASDAQ: TOMZ) | Salmonella in Eggs – Biosecurity at the Source – More Stocks Inside
October 15, 2025
Via
AB Newswire
Topics
Artificial Intelligence
Product Recall
Q3 Virtual Investor Summit: On-Demand Presentations Now Available
September 30, 2025
Via
ACCESS Newswire
Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free
September 16, 2025
Via
ACCESS Newswire
Planned Spin-Out to Focus on Gene Therapy for Type-1 and Type-2 Diabetes in Parallel to Treatments for Late Stage Lung Cancer: Genprex, Inc. (Nasdaq: GNPX)
September 04, 2024
Via
Get News
Positive Clinical Results with Promising Gene Therapy Treatment for Late Stage Lung Cancer; Life-Changing Developments for Cancer and Diabetes: Genprex, Inc. (Nasdaq: GNPX)
August 22, 2024
Via
Get News
Topics
Intellectual Property
Clinical Trials Commenced for Promising Acclaim-3 Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer: Genprex, Inc. (NASDAQ: GNPX)
May 14, 2024
Via
Get News
New Company Officers Appointed After Promising Preclinical Data on Gene Therapy for Anti-Tumor Mechanisms with Ability to Trigger Cancer Cell Death: Genprex, Inc. (NASDAQ: GNPX)
May 13, 2024
Via
Get News
BioMedNewsBreaks — Genprex Inc. (NASDAQ: GNPX) Announces Participation at Upcoming Investor, Industry Events
May 01, 2024
Via
Investor Brand Network
Topics
Intellectual Property
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPRL2 Gene Therapy
April 02, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering
March 25, 2024
Via
Investor Brand Network
TechMediaBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering
March 25, 2024
Via
Investor Brand Network
TinyGemsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering
March 19, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering
March 19, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Adds Korean Patent for Leading Drug Candidate to Growing International Patent Portfolio
March 13, 2024
Via
Investor Brand Network
Topics
Intellectual Property
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Preclinical Data to be Presented at Upcoming AACR Annual Meeting
March 06, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications
February 07, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications
February 07, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at This Month’s BIO CEO & Investor Conference
February 06, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient
February 05, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient
February 05, 2024
Via
Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) Granted Orphan Drug Designation in Small Cell Lung Cancer by FDA, Presented Data at Two October Events Focused on Lung Cancer
November 22, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at BIO-Europe 2023
November 01, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Schedules, Hosts Virtual Key Opinion Leader Event
October 20, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Unveil Encouraging Data on REQORSA(R) for Lung Cancer Treatment at 2023 AACR-NIH-EORTC Conference
October 04, 2023
Via
Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
September 21, 2023
From
Genprex, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Building Protection and Powerful IP Portfolio for Its Diabetes Gene Therapy Program
September 20, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
September 20, 2023
Via
Investor Brand Network
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
September 20, 2023
EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END
Via
FinancialNewsMedia
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.